vafseo
akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - sýklalyf - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.
celecoxib actavis hart hylki 200 mg
actavis group ptc ehf. - celecoxibum inn - hart hylki - 200 mg
celecoxib actavis hart hylki 100 mg
actavis group ptc ehf. - celecoxibum inn - hart hylki - 100 mg
adakveo
novartis europharm limited - crizanlizumab - blóðleysi, blóðkorn - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
celecoxib medical hart hylki 100 mg
medical ehf. - celecoxibum inn - hart hylki - 100 mg
celecoxib medical hart hylki 200 mg
medical ehf. - celecoxibum inn - hart hylki - 200 mg
celebra hart hylki 100 mg
upjohn eesv - celecoxibum inn - hart hylki - 100 mg
celebra hart hylki 200 mg
upjohn eesv - celecoxibum inn - hart hylki - 200 mg
cloxabix hart hylki 100 mg
williams & halls ehf - celecoxibum inn - hart hylki - 100 mg
cloxabix hart hylki 200 mg
williams & halls ehf - celecoxibum inn - hart hylki - 200 mg